Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)

Femoral Artery Occlusion Clinical Trial

— CONFIRM  

Official title:

A Prospective, Multicenter, Single Arm, Post-Approval Study of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02813577
• Other study ID #: CL0025-01
• Status: Terminated
• Phase: N/A
• Start date: April 20, 2018
• Est. completion date: February 18, 2019

Study information

• Verified date: April 2020
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The post approval study will enroll US female patients presenting with claudication or ischemic rest pain and an angiographically significant lesion in the superficial femoral or popliteal artery. Subjects are treated per Instructions For Use (IFU) with the Lutonix® Catheter. Subjects will have a Duplex Ultrasound (DUS) and clinical follow-up through two (2) years.

Description:

The Lutonix® 035 Drug Coated Balloon PTA Catheter (Lutonix® Catheter) has been approved by the Food and Drug Administration (P130024) for percutaneous transluminal angioplasty, after appropriate vessel preparation of de novo, restenotic, or in-stent restenotic lesions up to 300 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-7 mm. The purpose of this post-approval study is to assess the safety and effectiveness of the Lutonix® Catheter in the US female population. This study will enroll approximately 165 female patients at a minimum of 10 US centers and a maximum of 25.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: February 18, 2019
• Est. primary completion date: February 18, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Clinical Criteria

1. Non-pregnant female =18 years of age;

2. Rutherford Clinical Category 2-4;

3. Patient is willing to provide informed consent, is geographically stable, comply with the required follow up visits and testing schedule;

Angiographic Criteria

4. De novo or restenotic lesion(s) in native superficial femoral or popliteal arteries;

5. Lesion =70% stenosis by visual estimate;

6. Target reference vessel diameter of 4-7 mm;

7. A patent inflow artery free from significant lesion (=50% stenosis) as confirmed by angiography; (Treatment of target lesion acceptable after successful treatment of inflow artery lesions. Successful inflow artery treatment is defined as attainment of residual diameter stenosis =30% without death or major vascular complication.)

8. At least one patent native outflow artery to the ankle, free from significant (=50%) stenosis as confirmed by angiography after successful vessel preparation;

9. Successful antegrade wire crossing and vessel preparation (may include pre-dilatation) of the target lesion. Successful vessel preparation is defined by residual stenosis =30% without any major vascular complications;

10. No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment except for remote common femoral patch angioplasty separated by at least 2 cm from the lesion(s).

Exclusion Criteria

1. Life expectancy of <2 years;

2. Subject is currently participating in an investigational drug or device study, or previously enrolled in this study. Enrollment in another investigational drug or device study during the follow up period is not allowed;

3. History of stroke within 3 months;

4. History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of index procedure;

5. Renal failure or chronic kidney disease with serum creatinine =2.5 mg/L within 30 days of index procedure or treated with dialysis;

6. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel.

Related Conditions & MeSH terms

• Arterial Occlusive Diseases
• Constriction, Pathologic
• Femoral Artery Occlusion
• Femoral Artery Stenosis
• Popliteal Artery Occlusion
• Popliteal Artery Stenosis

Intervention

Device:
• Lutonix® 035 Drug Coated Balloon PTA Catheter
Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.

Locations

Country	Name	City	State
United States	Midwest Cardiovascular Research Foundation	Davenport	Iowa
United States	St. Vincent Medical Group	Indianapolis	Indiana
United States	Wellmont CVA Heart Institute	Kingsport	Tennessee
United States	Vascular Access Solutions	Orangeburg	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
C. R. Bard

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure	Index limb amputation includes above or below the ankle amputations.	12 months post index procedure
Primary	Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.	Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) = 2.5 and / or abnormal waveforms, or based on angiographic = 50% diameter stenosis.	12 months post index procedure
Secondary	Number of Participants With Freedom From All-cause Perioperative (= 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.		30 days post index procedure
Secondary	Number of Major Vascular Complications at 30 Days Post Index Procedure		30 days
Secondary	Number of Deaths (All Causes) at 30 Days Post Index Procedure		30 days post index procedure
Secondary	Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure		1, 6, 12 and 24 months post index procedure
Secondary	Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure		1, 6, 12 and 24 months post index procedure
Secondary	Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure		1, 6, 12 and 24 months post index procedure
Secondary	Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure		1, 6, 12 and 24 months post index procedure
Secondary	Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.		1, 6, 12 and 24 months
Secondary	Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline		1, 6, 12 and 24 months post index procedure
Secondary	Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure		1, 6, 12 and 24 months post index procedure
Secondary	Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline		1, 6, 12 and 24 months post index procedure

External Links

•   Lutonix® 035 Drug Coated Balloon PTA Catheter Instructions For Use